Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)
This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.
• Patients must have a histologically-confirmed diagnosis of CD30- positive/expressing peripheral T-cell lymphoma (PTCL). NOTE: All PTCL subtypes are eligible, except for adult T-cell leukemia/Lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL); ATLL and CTCL are excluded per exclusion criterion below. Examples of eligible subtypes include but are not limited to the following:
‣ AITL: Angioimmunoblastic T-cell lymphoma
⁃ EATL: Enteropathy-associated T-cell lymphoma
⁃ ENKTL: Extranodal Natural Killer/T-cell Lymphoma
⁃ FTCL: Follicular T-cell lymphoma
⁃ HSTCL: Hepatosplenic T-cell lymphoma
⁃ PTCL-NOS: Peripheral T-cell lymphoma, not otherwise specified
⁃ PTCL-TFH: Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
⁃ SPTCL: Subcutaneous Panniculitis-like T-cell Lymphoma
⁃ ALCL: Anaplastic Large Cell Lymphoma NOTE: CD30-positivity is defined as \>= 1% of cells expressing CD30 as detected by immunohistochemistry (IHC) and determined by local review.
• Patients must have received at least one prior line of systemic therapy and must have relapsed disease or secondary refractory disease meeting one of the below criteria:
‣ Disease that relapsed within \> 6 months after completion of frontline therapy; or
⁃ Disease that relapsed within any time after completion of secondary/subsequent lines of therapy; or
⁃ Disease that was refractory to secondary/subsequent lines of therapy NOTE: Patients who have primary relapsed/refractory disease with relapse within 6 months of frontline treatment are not eligible. See exclusion criterion below NOTE: Exclusions on receipt of prior brentuximab vedotin are described in exclusion criterion below. Exclusions on receipt of prior immunotherapy are described in exclusion criterion below.
• Patients must be \>= 18 years of age
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Absolute neutrophil count (ANC) \>= 1,000/mcL
• Platelets \>= 50,000/mcL
• Hemoglobin \>= 9 g/dL or \>= 5.6 mmol/L (without transfusion or erythropoietin-dependency within =\< 7 days prior to assessment)
• Measured or calculated creatinine clearance \>= 60 mL/min
‣ Creatinine clearance should be calculated per institutional standard
• Serum total bilirubin =\< 1.5 X upper limit of normal (ULN) OR direct bilirubin =\< ULN for patients with total bilirubin levels \> 1.5 ULN
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 X ULN OR =\< 5 X ULN for patients with liver metastases
• Female patients of reproductive potential must have a negative urine or serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. NOTE: In the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for the subject to start receiving study medication
• Female patients of reproductive potential must be willing to use an adequate method of contraception starting \>= 7 days prior to the first dose of study therapy and through 23 weeks after the last dose. Male patients of reproductive potential must agree to use an adequate method of contraception starting \>= 7 days prior to the first dose of study therapy and through 31 weeks after the last dose. NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
• Patients must have an fludeoxyglucose F 18-positron emission tomography-computed tomography (18FDG-PET-CT) scan (preferred) or CT scan of chest, abdomen, and pelvis (and neck if clinically indicated) at baseline and must have measurable disease per 2014 Lugano Criteria. The same imaging modality should be used throughout the course of study treatment to assess tumor response. NOTE: Imaging with contrast is preferred, but imaging without contrast will be accepted if the use of contrast is not clinically indicated
• Patients must have the ability to understand and the willingness to sign a written informed consent form prior to registration on study